Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis
Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis
Polypharmacy in older adults is associated with multiple negative consequences that may affect muscular function, independently from the presence of medical conditions. The aim of this systematic review and meta-analysis was to investigate the association of sarcopenia with polypharmacy and higher number of medications. A systematic literature search of observational studies using PubMed, Web of Science, Scopus and Cochrane Library databases was conducted from inception until June 2022. To determine if sarcopenia is associated with a higher risk of polypharmacy and increased number of medications, a meta-analysis using a random-effects model was used to calculate the pooled effects (CRD42022337539). Twenty-nine studies were included in the systematic review and meta-analysis. Sarcopenia was associated with a higher prevalence of polypharmacy (odds ratio [OR]: 1.65, 95% confidence interval [CI] [1.23, 2.20], I
2 = 84%, P < 0.01) and higher number of medications (mean difference: 1.39, 95% CI [0.59, 2.19], I
2 = 95%, P < 0.01) compared with individuals without sarcopenia. Using meta-regression, a high variance was observed due to different populations (i.e., community-dwelling, nursing home residents, inpatients, outpatients) for both outcomes of polypharmacy (r = -0.338, SE = 0.1669, 95% CI [-0.67, -0.01], z = -2.03, P = 0.04) and number of medications (r = 0.589, SE = 0.2615, 95% CI [0.08, 1.10], z = 2.25, P = 0.02). This systematic review and meta-analysis reported a significantly increased risk of polypharmacy and higher number of medications in people with sarcopenia compared with individuals without this condition. Future research should clarify whether the specificity and number of medications is a direct contributor in accelerating the progression of muscle wasting and dysfunction contributing to sarcopenia in older adults.
ageing, medications, physical function, polypharmacy, sarcopenia
671 - 683
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Prokopidis, Konstantinos
31f1f079-d93c-4ecd-9de6-df7759180fd8
Giannos, Panagiotis
10de9888-0ee7-4746-91c6-7cd29512cac5
Reginster, Jean Yves
33684a35-87f7-4b8d-bb91-4da2b809f855
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d
Petrovic, Mirko
7bbd64fb-c748-4447-b4d5-2aa77527ec12
Cherubini, Antonio
09bc8d13-db3e-46dd-9319-6c0a94638eb8
Triantafyllidis, Konstantinos K.
fe083a9a-1707-4372-9d91-ca97422cc12d
Kechagias, Konstantinos S.
d354309b-7c92-43fb-a9df-931c63a82968
Dionyssiotis, Yannis
72528266-e135-4460-b441-b5a6dfa67bb9
Cesari, Matteo
7e731742-9266-4ed3-a3d9-e5c51f468808
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Scott, David
4f47b8c1-5f9c-42a3-b046-72512a209cca
Barbagallo, Mario
253443e1-cdf1-4549-ac04-c18c27d11d1a
Veronese, Nicola
a9a97f63-a828-45a3-bae0-68182c5a44fd
April 2023
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Prokopidis, Konstantinos
31f1f079-d93c-4ecd-9de6-df7759180fd8
Giannos, Panagiotis
10de9888-0ee7-4746-91c6-7cd29512cac5
Reginster, Jean Yves
33684a35-87f7-4b8d-bb91-4da2b809f855
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d
Petrovic, Mirko
7bbd64fb-c748-4447-b4d5-2aa77527ec12
Cherubini, Antonio
09bc8d13-db3e-46dd-9319-6c0a94638eb8
Triantafyllidis, Konstantinos K.
fe083a9a-1707-4372-9d91-ca97422cc12d
Kechagias, Konstantinos S.
d354309b-7c92-43fb-a9df-931c63a82968
Dionyssiotis, Yannis
72528266-e135-4460-b441-b5a6dfa67bb9
Cesari, Matteo
7e731742-9266-4ed3-a3d9-e5c51f468808
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Scott, David
4f47b8c1-5f9c-42a3-b046-72512a209cca
Barbagallo, Mario
253443e1-cdf1-4549-ac04-c18c27d11d1a
Veronese, Nicola
a9a97f63-a828-45a3-bae0-68182c5a44fd
Ibrahim, Kinda, Prokopidis, Konstantinos, Giannos, Panagiotis, Reginster, Jean Yves, Bruyère, Olivier, Petrovic, Mirko, Cherubini, Antonio, Triantafyllidis, Konstantinos K., Kechagias, Konstantinos S., Dionyssiotis, Yannis, Cesari, Matteo, Ibrahim, Kinda, Scott, David, Barbagallo, Mario and Veronese, Nicola
(2023)
Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis.
Journal of Cachexia, Sarcopenia and Muscle, 14 (2), .
(doi:10.1002/jcsm.13190).
Abstract
Polypharmacy in older adults is associated with multiple negative consequences that may affect muscular function, independently from the presence of medical conditions. The aim of this systematic review and meta-analysis was to investigate the association of sarcopenia with polypharmacy and higher number of medications. A systematic literature search of observational studies using PubMed, Web of Science, Scopus and Cochrane Library databases was conducted from inception until June 2022. To determine if sarcopenia is associated with a higher risk of polypharmacy and increased number of medications, a meta-analysis using a random-effects model was used to calculate the pooled effects (CRD42022337539). Twenty-nine studies were included in the systematic review and meta-analysis. Sarcopenia was associated with a higher prevalence of polypharmacy (odds ratio [OR]: 1.65, 95% confidence interval [CI] [1.23, 2.20], I
2 = 84%, P < 0.01) and higher number of medications (mean difference: 1.39, 95% CI [0.59, 2.19], I
2 = 95%, P < 0.01) compared with individuals without sarcopenia. Using meta-regression, a high variance was observed due to different populations (i.e., community-dwelling, nursing home residents, inpatients, outpatients) for both outcomes of polypharmacy (r = -0.338, SE = 0.1669, 95% CI [-0.67, -0.01], z = -2.03, P = 0.04) and number of medications (r = 0.589, SE = 0.2615, 95% CI [0.08, 1.10], z = 2.25, P = 0.02). This systematic review and meta-analysis reported a significantly increased risk of polypharmacy and higher number of medications in people with sarcopenia compared with individuals without this condition. Future research should clarify whether the specificity and number of medications is a direct contributor in accelerating the progression of muscle wasting and dysfunction contributing to sarcopenia in older adults.
Text
J cachexia sarcopenia muscle - 2023 - Prokopidis - Sarcopenia is associated with a greater risk of polypharmacy and number
- Version of Record
More information
Accepted/In Press date: 16 January 2023
e-pub ahead of print date: 13 February 2023
Published date: April 2023
Additional Information:
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Keywords:
ageing, medications, physical function, polypharmacy, sarcopenia
Identifiers
Local EPrints ID: 476137
URI: http://eprints.soton.ac.uk/id/eprint/476137
ISSN: 2190-5991
PURE UUID: 6299d5ce-d873-4700-9a05-17c769c67555
Catalogue record
Date deposited: 12 Apr 2023 16:47
Last modified: 17 Mar 2024 03:34
Export record
Altmetrics
Contributors
Author:
Konstantinos Prokopidis
Author:
Panagiotis Giannos
Author:
Jean Yves Reginster
Author:
Olivier Bruyère
Author:
Mirko Petrovic
Author:
Antonio Cherubini
Author:
Konstantinos K. Triantafyllidis
Author:
Konstantinos S. Kechagias
Author:
Yannis Dionyssiotis
Author:
Matteo Cesari
Author:
David Scott
Author:
Mario Barbagallo
Author:
Nicola Veronese
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
